Kidney Cancer: Dual Immunotherapy with Opdivo and Yervoy and Survival
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
For patients with metastatic renal cell carcinoma (RCC), the choice of first-line therapy is a critical determinant of long-term outcomes. The Phase 3 CheckMate-214 trial, published in The Lancet Oncology, has established dual immunotherapy with Opdivo (Nivolumab) and Yervoy (Ipilimumab) as a standard of care for intermediate and poor-risk patients.
1. Advance Survival Data from CheckMate-214
The trial compared the dual immunotherapy combo against the standard TKI Sunitinib (Sutent):
- Overall Survival (OS): The Opdivo+Yervoy group showed a 34% reduction in the risk of death compared to the Sunitinib group.
- Durable Responses: Patients treated with immunotherapy often experience 'tail-of-the-curve' benefits, where tumor control lasts for years.
- Complete Remission: A significant number of patients (9%) achieved a complete response, a rare outcome with traditional targeted therapies.
2. Managing the Immune System
While avoiding the side effects of traditional chemotherapy, dual immunotherapy requires expert monitoring for immune-related adverse events (irAEs). Treatment should be managed by medical institutions experienced in monitoring and handling these reactions.
Medical Supporter: Your Partner for Precision Oncology in Japan
Access kidney cancer specialists and advanced immunotherapy protocols in Japan through our professional coordination services.
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.